Neoadjuvant Chemoradiotherapy Plus Atezolizumab for Resectable Esophageal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Chemoradiotherapy Combined With Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single Arm Phase II Feasibility Trial (PERFECT)
Clin. Cancer Res 2021 Jan 27;[EPub Ahead of Print], T van den Ende, N Clercq, MI van Berge Henegouwen, SS Gisbertz, D Geijsen, R Verhoeven, SL Meijer, S Schokker, M Dings, JJGHM Bergman, N Haj Mohammad, JP Ruurda, R van Hillegersberg, S Mook, M Nieuwdorp, TD de Gruijl, TTD Soeratram, B Ylstra, NCT van Grieken, MF Bijlsma, MCCM Hulshof, HW van LaarhovenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.